White Paper: From Data to Deal: Price Transparency Data for Private Equity Investors

In this white paper, Elvira Makk Frid Frid examines how publicly disclosed negotiated rates can inform healthcare investment analysis. Without information on negotiated rates, the true picture of healthcare prices has remained blurry. The recent Price Transparency rules promise to bring some much-needed clarity.

As the healthcare landscape continues to evolve, price transparency has the potential to shift how investors evaluate opportunities and risks, providing a clearer foundation for strategy and decision-making.